Search

The purpose of this study was to compare the effects of the radial forearm free flap (RFFF) and groin soft tissue free flap (GSFF) on the quality of life (QoL) of patients undergoing reconstructive surgery after resection for oral cancer. A retrospective analysis of 48 patients was performed. The Vancouver Scar Scale (VSS), University of Washington Quality of Life (UW-QOL) questionnaire, and 14-item Oral Health Impact Profile (OHIP-14) questionnaire were used to evaluate the donor site scars and QoL of the patients. The postoperative hospital stay was significantly longer in the RFFF group than in the GSFF group (P = 0.001). Furthermore, the total VSS score (P = 0.011), VSS score for pigmentation (P 0.001), and OHIP-14 scores for psychological discomfort (P = 0.026) and social disability (P = 0.044) were all significantly higher in the RFFF group than in the GSFF group, while the UW-QOL scores for appearance (P = 0.037) and mood (P = 0.036) were significantly lower in the RFFF group than in the GSFF group. Compared with the RFFF, the GSFF scar is more concealed, with better aesthetics at the donor site, and this flap can result in improved postoperative QoL for patients with oral cancer.

目的 探讨真性红细胞增多症（PV）患者干扰素和（或）羟基脲治疗后症状负荷改善与血液学疗效之间的关系。 方法 对190例符合WHO（2016）诊断分型标准、接受干扰素和（或）羟基脲连续治疗≥6个月的PV患者，分别应用外周血细胞计数和骨髓增殖性肿瘤总症状评估量表（MPN-10）评价患者血液学疗效和症状负荷。 结果 全部190例PV患者中，男93例（48.9％），女97例（51.1％）。进行MPN-10评分时，患者中位年龄为60（32～82）岁。全部患者中位MPN-10总分为9（0～67）分，干扰素+羟基脲组（27例）为11（0～67）分，显著高于干扰素组［64例，6（0～56）分，P＝0.019］和羟基脲组［99例，9（0～64）分，P＝0.047］，而干扰素组与羟基脲组差异无统计学意义（P＝0.421）。28.9％（55/190）的患者存在重度症状（单项症状评分≥7分或总分≥44分），干扰素组、羟基脲组、干扰素+羟基脲组重度症状患者占比分别为23.4％、29.3％、40.7％，组间比较差异均无统计学意义（P>0.05）。全部190例患者中，进行MPN-10评分时71例（37.4％）获得完全血液学缓解（CHR），仅55例（28.9％）获得疾病充分控制（获得CHR且无重度症状）。未获得疾病充分控制的患者包括：血细胞增高80例（42.1％），获得CHR但伴重度症状16例（8.4％），血细胞增高且伴重度症状39例（20.5％）。PLT>400×109/L患者中存在重度症状患者比例、MPN-10总分中位数均高于PLT≤400×109/L患者［40.8％（20/49）对24.8％（35/141），P＝0.044；14（0～67）分对7（0～56）分，P＝0.038］。PLT>400×109/L是存在重度症状的危险因素（HR＝2.089，95％CI 1.052～4.147，P＝0.035）。 结论 经干扰素和（或）羟基脲治疗后，PV患者症状负荷未获满意控制仍较突出，部分患者虽然获得CHR，仍存在重度症状负荷。PLT>400×109/L是干扰素和羟基脲治疗后患者存在重度症状的危险因素。

目的 评价MIPSS70-plus预后积分系统对中国原发性骨髓纤维化（PMF）患者的预后评估价值。 方法 回顾性分析113例PMF患者的临床资料，应用Log-rank和COX回归模型进行预后相关因素分析；应用似然比检验比较MIPSS70-plus和动态国际预后积分系统（DIPSS）的预后评估效能。 结果 113例PMF患者中男71例，女42例，中位年龄55（20～70）岁。依据MIPSS70-plus染色体核型分组标准，染色体核型预后良好组90例（79.6%），预后不良组23例（20.4%）。二代测序基因突变检测结果示，JAK2V617F突变63例（55.8%），CALR外显子9突变20例（17.7%）（其中1型CALR突变15例，2型CALR突变5例），MPLW515突变5例（4.4%），25例（22.1%）未检测到JAK2、MPL和CALR基因突变（三阴性）。高分子风险（HMR）突变检出率依次为ASXL1突变44例（38.9%）、SRSF2突变8例（7.1%）、IDH1/2突变5例（4.4%）、EZH2突变4例（3.5%）；51例患者（45.1%）有1种以上高危基因突变。MIPSS70-plus预后积分低危组、中危组、高危组、极高危组分别为28例（26.7%）、20例（19.0%）、41例（39.0%）、16例（15.3%），2年预期总生存率分别为100%、89.7%（95%CI 76.2%～100.0%）、64.8%（95%CI 47.0%～82.6%）、35.0%（95%CI 10.3%～59.7%）（P

目的 分析骨髓纤维化（MF）患者RAS基因突变的分子特征及其临床特点和预后意义。 方法 收集2011年12月至2019年12月在我中心有二代基因测序数据的226例MF患者临床资料，回顾性分析RAS基因突变特征、与临床和实验室参数之间的关系，及对总生存（OS）期的影响。 结果 226例原发性骨髓纤维化（PMF）及真性红细胞增多症（PV）或原发性血小板增多症（ET）后骨髓纤维化（post-PV/ET MF）患者中，共14例（6.2％）检出RAS基因突变：NRAS突变9例（4.0％），KRAS突变8例（3.5％），NRAS及KRAS突变并存3例（1.3％）。所有NRAS突变均发生在第12-13号密码子。RAS基因突变多为亚克隆突变，常与SETBP1、SRSF2、MPL共同发生。伴RAS基因异常患者平均突变基因个数（3.36个）与无RAS基因异常组（1.77个）相比，差异有统计学意义（P

目的 比较原发性骨髓纤维化（PMF）和骨髓增生异常综合征伴骨髓纤维化（MDS-MF）患者纤维驱动细胞的差异。 方法 随机选取MF-0/1、MF-2和MF-3级的初诊PMF和MDS患者各10例，骨髓活检组织切片利用特异性免疫荧光抗体标记Gli1、LeptinR、平滑肌肌动蛋白（α-SMA）、CD45和ProcollagenⅠ，共聚焦显微镜成像后利用Fiji-ImageJ软件计数Gli1+、LeptinR+细胞及α-SMA+、α-SMA+/Gli1+、α-SMA+/LeptinR+和ProcollagenⅠ+/CD45+等纤维驱动细胞。 结果 MF-2/3级PMF和MDS患者LeptinR+、α-SMA+、α-SMA+/Gli1+和ProcollagenⅠ+/CD45+等细胞计数均显著高于MF-0/1级患者（P0.05）。但MF-2/3级患者中，PMF患者ProcollagenⅠ+/CD45+计数显著高于MDS患者（P＝0.007），其他纤维驱动细胞计数相比较差异均无统计学意义（P>0.05）。MF分级及纤维驱动细胞计数与PMF和MDS患者总生存时间无相关性。 结论 PMF患者α-SMA+细胞来源于Gli1+和LeptinR+细胞，而MDS-MF患者α-SMA+细胞仅来源于Gli1+细胞；PMF患者ProcollagenⅠ+/CD45+细胞计数显著高于MDS-MF患者。

目的 探讨骨髓增生异常综合征（MDS）RAS基因突变的分子学特征及其对预后的影响。 方法 收集2011年12月至2018年12月新诊断且完成二代测序的776例MDS患者病例资料，回顾性分析RAS基因突变患者的临床及分子学特征，并比较不同突变状态对总生存（OS）的影响。 结果 共52例（6.7％）患者伴有RAS基因突变，NRAS突变38例（4.9％），KRAS突变18例（2.3％），4例（0.5％）同时伴NRAS及KRAS突变，全部NRAS突变及65％的KRAS突变位于第12、13及61号密码子。RAS基因突变与PTPN11、FLT3、U2AF1、RUNX1、WT1、ETV6及NPM1突变呈显著正相关（Q

OBJECTIVE: To explore the feasibility, safety and mid-term outcome of minimally invasive cardiac surgery coronary artery bypass grafting (MICS CABG) surgery. METHODS: Data of patients who underwent MICS CABG between November 2015 and November 2017 in Peking University Third Hospital were retrospectively analyzed. Results were compared with the patients who underwent off-pump coronary aortic bypass grafting (OPCABG) surgery over the same period. The two groups were matched in propensity score matching method according to age, gender, left ventricular ejection fraction, body mass index, severity of coronary artery disease, smoking, diabetes mellitus, hypertension, hyperlipidemia, renal insufficiency, history of cerebrovascular accident, and history of chronic obstructive pulmonary disease (COPD). RESULTS: There were 85 patients in MICS CABG group, including 68 males (80.0%) and 17 females (20%), with an average age of (63.8±8.7) years; 451 patients were enrolled in OPCABG group, and 85 patients were matched by propensity score as control group (OPCABG group). There was no significant difference in general clinical characteristics (P>0.05). The average grafts of MICS CABG and OPCABG were 2.35±0.83 and 2.48±0.72 respectively (P=0.284). No conversion to thoracotomy in MICS CABG group or cardiopulmonary bypass in neither group occurred. There was no significant difference in the major adverse cardiovascular events (MACCEs, 1.17% vs. 3.52%), reoperation (2.34 vs. 3.52%), new-onset atrial fibrillation rate (4.70% vs. 3.52%) or new-onset renal insufficiency rate (1.17% vs. 0%) between MICS CABG group and OPCABG group (P>0.05). The operation time in MICS CABG group was longer than that in OPCABG group [(282.8±55.8) min vs. (246.8±56.9) min, P < 0.05], while the time of ventilator supporting(16.9 h vs. 29.6 h), hospitalization in ICU [(29.3±20.8) h vs. (51.5±48.3) h] and total hospitalization [(18.3±3.2) d vs. (25.7±4.2) d] in MICS CABG group were shorter than those in OPCABG group (P < 0.05). The total patency rate (A+B levels) of MICS CABG was 96.5% after surgery. There was no significant difference in MACCEs rate between the two groups [1.18%(1/85) vs. 3.61%(3/83), P>0.05] in 1-year follow up. CONCLUSION: The MICS CABG surgery is a safe and feasible procedure with good clinical results in early and mid-term follow-up.

心血管疾病严重威胁着我国居民的健康。生物钟在心血管系统的生理过程中起着重要的调节作用，包括调节血压、心脏收缩和心率等。在环境周期信号的作用下，生物钟基因及其编码的蛋白质组成转录-翻译反馈环路，通过神经传导和体液途径实现信号输出，从而调节生物体的生理、生化和行为的昼夜节律。心血管疾病的发病时间具有昼夜变化的特点，一些生物钟基因表达的改变促进了心血管疾病的进展。该文介绍了心血管系统的昼夜节律，整理总结了高血压、动脉粥样硬化与心肌梗死等疾病中的相关生物钟基因及其分子机制。对昼夜节律和生物钟的研究为心血管疾病的预防和治疗提供了新思路。.

目的 调查我国医师和患者对Ph阴性骨髓增殖性肿瘤（MPN）症状负荷、治疗目标和疾病管理的理解，探寻医师和患者对疾病治疗沟通的差异，观察MPN疾病负荷对患者生活的影响。 方法 采用国际MPN Landmark调查问卷，于2018年9月至11月进行现场调查。 结果 共100名医师和298例患者[原发性血小板增多症（ET）122例，真性红细胞增多症（PV）116例，骨髓纤维化（MF）60例]参与问卷调查。90％的医师认为他们会根据预后风险评估对患者进行危度分组，然而只有67％的患者知道自己的预后分组。MF患者最常见的症状是疲劳/乏力（63％）、活动力不佳（48％）和腹部不适（47％）；PV患者最常见的症状是头晕/眩晕（63％）、面部潮红（54％）和活动力不佳（48％）；ET患者最常见的症状是头晕/眩晕（58％）、活动力不佳（49％）和疲劳/乏力（40％）。与PV（46％）和ET（52％）患者相比，MF患者情绪负担大的比例最高（62％）。分别有19％和30％的患者认为MPN严重影响了工作或日常活动的能力。47％的MPN患者有时或经常需要被看护，最近7 d看护人员的平均帮助时间为14.4 h。25％的患者认为疾病没有导致经济困难，66％的患者认为在不同程度上因病致贫，9％的患者认为疾病明显致贫。在诊断时，医师对19％的MF、23％的PV和26％的ET患者建议观察，而不推荐药物治疗。MF的治疗目标医师和患者基本一致，认为MF的主要治疗目标除了治愈以外，为改善症状、提高生活质量和延缓疾病进展。PV和ET患者认为他们的主要治疗目标除了治愈以外为症状改善（分别为82％和80％），这与医师的首要目标为预防血管/血栓事件（分别为53％和70％）是不一致的。从医师的角度看，对医患沟通的满意度为88％；从患者的角度看，对医患沟通的满意度为89％。18％的患者经常认为自己的状况比医师意识到的要差得多。 结论 高症状负荷明显影响MPN患者的生活质量，导致沉重的情绪负担、降低工作效率、导致经济困难，给MPN患者的治疗尚需提供额外的支持来应对MPN带来的情绪影响。医师和患者在治疗目标上存在不一致性，应采用更积极开放的沟通以使患者和医师能够在治疗目标和疾病管理上达成一致。

阻塞性睡眠呼吸暂停综合征（obstructive sleep apnea syndrome, OSAS）在儿童中是一种常见的睡眠呼吸障碍疾病。由于腺样体扁桃体肥大是OSAS儿童最主要的病因，因此腺样体扁桃体切除术是其首选治疗方法。研究发现，手术可改善OSAS儿童的睡眠呼吸障碍，但术后仍有部分患儿有残留OSAS症状，尤其在中重度患儿中更为常见。手术在改善睡眠呼吸障碍症状、神经认知、行为、生活质量和多导睡眠监测结果等方面，常因各研究中样本量大小、疾病严重程度、术后随访时间的不同，评估出的手术治疗效果及影响手术疗效的预测因素存在差异。本文主要阐述OSAS儿童腺样体扁桃体切除术后的治疗效果，并讨论OSAS儿童术后残留症状的预测因素。一方面可对OSAS儿童腺样体扁桃体术的治疗效果进行有效评估，另一方面可在手术后进行针对性随访，从而指导临床的个体化治疗并合理利用医疗资源。.

目的 研究伴环状铁粒幼红细胞增多（RS）的骨髓增生异常综合征（MDS-RS）患者的基因突变特征及其临床意义。 方法 收集2001年1月至2019年6月于中国医学科学院血液病医院新诊断的255例原发性MDS-RS患者资料。129例采用一代测序、126例采用包含112个血液肿瘤相关基因的二代测序（NGS）进行基因突变分析。 结果 共193例（75.7%）检出SF3B1突变，其中SF3B1 K700E突变147例（76.2%）。非SF3B1基因突变较常见的有TET2（16.7%）、ASXL1（14.3%）、U2AF1（11.1%）、TP53（7.9%）、SETBP1（6.3%）和RUNX1（6.3%）。RS 5%～0.05）。在114例NGS检出SF3B1突变的患者中，RS 5%～

目的 探讨平均红细胞体积（MCV）对骨髓增生异常综合征（MDS）预后的影响。 方法 收集2009年12月至2017年12月我中心新诊断、无红细胞输注史的321例原发性MDS患者，回顾性分析MCV水平对整体及不同骨髓原始细胞水平患者总生存（OS）期的影响。 结果 全部患者按照MCV水平高低分为MCV≤100 fl组（148例）和MCV>100 fl组（173例）。MCV≤100 fl组患者中位OS时间为27（95%CI 19~35）个月，MCV>100 fl组患者中位OS时间为72（95%CI 5~139）个月，差异有统计学意义（P100 fl者显著缩短（P=0.002）；而在骨髓原始细胞≥5%的患者中，MCV水平对OS的影响不显著（P=0.078）。在纳入其余临床指标及基因突变校正后，MCV≤100 fl仍为骨髓原始细胞100 fl组[90（42~153）g/L对78.5（28~146）g/L，P=0.015]，IPSS-R高危/极高危组比例及IPSS-R染色体核型分组差/很差比例明显高于MCV>100 fl组，差异有统计学意义（28.8%对10.8%，P=0.003；24.7%对12.9%，P=0.049）。MCV≤100 fl组患者平均基因突变数目较MCV>100 fl组多（0.988个对0.769个，P=0.064），SF3B1突变较MCV>100 fl组少见（4.7%对15.4%，P=0.018）。 结论 MCV≤100 fl为骨髓原始细胞

目的 探讨符合WHO（2016）诊断分型标准的骨髓增生异常综合征（MDS）5q−综合征患者的临床特征、来那度胺（LEN）疗效和生存情况。 方法 回顾性分析2008年1月至2018年4月于中国医学科学院血液病医院就诊的77例符合WHO（2016）诊断分型标准的MDS 5q−综合征患者临床资料，比较单纯5q−与5q−伴1个非−7/7q−的其他染色体异常（ACA）患者临床特征、疗效及生存情况，并比较LEN与非LEN药物治疗的疗效与生存情况。 结果 77例患者中，单纯5q−者64例，5q−伴ACA者13例，确诊时5q−伴ACA患者的中位年龄显著低于单纯5q−患者[58（29~64）岁对63（31~82）岁，z=2.164，P=0.030]。5q−伴ACA患者CD41免疫组化染色小巨核细胞（直径≤40 µm）检出率（91.7%，11/12）显著高于单纯5q−患者（60.0%，33/55）（P=0.046）。可评估LEN疗效的29例患者中，单纯5q−患者（19例）与5q−伴ACA患者（10例）血液学总反应率（78.9%对80.0%）、血液学完全缓解（CR）率（57.9%对60.0%）、细胞遗传学反应（CyR）率[69.2%（9/13）对66.7%（4/6）]、完全细胞遗传学反应（CCyR）率[61.5%（8/13）对33.3%（2/6）]相当。单纯5q−与5q−伴ACA患者中位总生存（OS）时间差异无统计学意义（62个月对78个月，P=0.313）。29例LEN组患者的血液学总反应率（79.3%对36.0%）、CR率（58.6%对8.0%）、CyR率[68.4%（13/19）对11.1%（1/9）]、CCyR率[52.6%（10/19）对0（0/9）]均高于非LEN组患者（25例），但两组患者中位OS时间差异无统计学意义（78个月对62个月，P=0.297）。 结论 单纯5q−与5q−伴ACA患者临床特征大体相似，两组患者LEN疗效、中位OS时间无明显差异。LEN治疗5q−综合征患者的疗效肯定，优于非LEN药物。

NiWP alloy coatings were prepared by electrodeposition, and the effects of ferrous chloride ( $$\hbox {FeCl}_{2})$$ , sodium tungstate ( $$\hbox {Na}_{2}\hbox {WO}_{4})$$ and current density ( $$D_{\mathrm{K}}$$ ) on the properties of the coatings were studied. The results show that upon increasing the concentration of $$\hbox {FeCl}_{2}$$ , initially the Fe content of the coating increased and then tended to be stable; the deposition rate and microhardness of coating decreased when the cathodic current efficiency ( $$\eta $$ ) initially increased and then decreased; and for a $$\hbox {FeCl}_{2}$$ concentration of $$3.6\, \hbox {g\,l}^{-1}$$ , the cathodic current efficiency reached its maximum of 74.23%. Upon increasing the concentration of $$\hbox {Na}_{2}\hbox {WO}_{4}$$ , the W content and microhardness of the coatings increased; the deposition rate and the cathode current efficiency initially increased and then decreased. The cathodic current efficiency reached the maximum value of 70.33% with a $$\hbox {Na}_{2}\hbox {WO}_{4}$$ concentration of 50 g $$\hbox {l}^{-1}$$ , whereas the deposition rate is maximum at 8.67 $$\upmu \hbox {m}\,\hbox {h}^{-1}$$ with a $$\hbox {Na}_{2}\hbox {WO}_{4}$$ concentration of $$40\, \hbox {g\,l}^{-1}$$ . Upon increasing the $$D_{\mathrm{K}}$$ , the deposition rate, microhardness, Fe and W content of the coatings increased, the cathodic current efficiency increases first increased and then decreased. When $$D_{\mathrm{K}}$$ was 4 A dm $$^{-2}$$ , the current efficiency reached the maximum of 73.64%.

目的 探讨伴TP53基因异常骨髓增生异常综合征（MDS）患者的临床特征及预后。 方法 回顾性分析2009年10月至2017年12月中国医学科学院血液病医院新诊断的584例原发性MDS患者临床资料，采用包含112个血液肿瘤相关基因的靶向测序技术进行突变分析，并采用间期荧光原位杂交（FISH）技术检测TP53基因缺失。分析TP53基因突变和（或）缺失与临床特征之间的关系及其对患者总生存（OS）的影响。 结果 42例（7.2%）伴TP53基因异常，其中单纯基因突变31例（5.3%），单纯基因缺失8例（1.4%），同时伴有突变和缺失3例（0.5%）。34例伴TP53基因突变患者中共检测到37个TP53突变，其中35个位于DNA结合结构域（第5~8号外显子），1个位于第10号外显子，1个为剪切位点突变。伴TP53基因异常组的平均基因突变数目（2.52个）显著高于无异常组（1.96个）（z=−2.418，P=0.016）。伴TP53基因异常患者的中位年龄[60（21~78）岁]高于无异常患者[52（14~83）岁]（z=−2.188，P=0.029）；伴TP53基因异常组中复杂核型比例、IPSS较高危组（中危-2及高危）比例显著高于无异常组（P值均

目的 探讨芦可替尼（RUX）联合PTD方案（泼尼松+沙利度胺+达那唑）治疗骨髓纤维化（MF）的疗效和安全性。 方法 对符合2016年WHO的MF诊断标准的MF患者，采用芦可替尼（RUX）联合PTD方案治疗，并评价该方案的临床疗效、血细胞计数变化和不良反应。 结果 7例MF患者纳入研究，其中原发性骨髓纤维化（PMF）6例，原发性血小板增多症后骨髓纤维化（post-ET MF）1例；JAK2V617F突变4例，CARL突变1例，MPLW515突变1例，以上3种始动基因突变均阴性1例。7例患者治疗前均有肋缘下可触及的脾肿大。7例患者中5例获得临床改善，2例疾病稳定。7例患者均有不同程度的临床症状改善，6例患者有不同程度的脾脏缩小。3例患者接受芦可替尼单药治疗，均出现不同程度的血红蛋白浓度和血小板计数下降，改用芦可替尼联合PTD方案后血红蛋白浓度和血小板计数均明显上升。所有7例接受芦可替尼联合PTD方案治疗患者的血红蛋白浓度中位上升值为30（18~54）g/L，血小板计数中位上升值为116（13~369）×109/L，其中3例患者因血小板计数明显上升而调高芦可替尼剂量。全部7例患者均未发生血液学不良反应，未发生Ⅲ/Ⅳ级非血液学不良反应，Ⅰ/Ⅱ级非血液学不良反应包括便秘、腹胀、下肢水肿、丙氨酸转氨酶升高和齿龈感染各1例。 结论 芦可替尼联合泼尼松、沙利度胺和达那唑治疗MF患者，可减少芦可替尼的血液学不良反应，使血红蛋白和血小板计数上升、提高临床疗效，且安全性好。

The effect of plating temperatures between 60 and 90°C on structure and corrosion resistance for electroless NiWP coatings on AZ91D magnesium alloy substrate was investigated. Results show that temperature has a significant influence on the surface morphology and corrosion resistance of the NiWP alloy coating. An increase in temperature will lead to an increase in coating thickness and form a more uniform and dense NiWP coatings. Moreover, cracks were observed by SEM in coating surface and interface at the plating temperature of 90°C. Coating corrosion resistance is highly dependent on temperature according to polarization curves. The optimum temperature is found to be 80 ∘ C and the possible reasons of corrosion resistance for NiWP coating have been discussed.

Synopsis We present (e, e+ion) measurements for double ionization of nitrogen and oxygen molecules employing the reaction microscope in which the momentum vectors for final-state charged reaction products are determined experimentally. By measuring the final state electrons in coincidence with the molecular dication, the related electronic states and, thus, the production mechanisms of these dications could be identified and studied in detail.

In this paper, ternary NiFeW alloy coatings were prepared by jet electrodeposition, and the effects of lord salt concentration, jet speed, current density and temperature on the properties of the coatings, including the composition, microhardness, surface morphology, structure and corrosion resistance, were investigated. Results reveal that the deposition rate reaches a maximum value of 27.30 $$\upmu \hbox {m}\hbox { h}^{-1}$$ , and the total current efficiency is above 85%. The maximum microhardness is 605 HV, and the wear and corrosion resistance values of the alloy coating are good. Moreover, the ternary NiFeW alloy coating is smooth and bright, and it presents a dense cellular growth. The alloy plating is nanocrystalline and has face-centered cubic structure.

To investigate the expression of long non-coding RNA DUXAP10 in ovarian cancer and its effect on ovarian cancer cell lines HO8910 and A2780 cells.Search the microarray dataset from the Gene Expression Omnibus (GEO) database using the keywords "ovarian cancer" and "GPL570". The differentially expressed genes in ovarian cancer tissues and normal ovarian tissues were analyzed by bioinformatics. Normal ovarian epithelial cells IOSE386, ovarian cancer HEY, HO8910 and A2780 cell lines were cultured. Cell proliferation assay was detected by CCK8 method and cloning formation assay was done. Quantitative Real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of RNA.The results showed that the expression of DUXAP10 in ovarian cancer tissues was significantly higher than that in normal ovarian tissues, which was consistent with those of TCGA. Clinical data analysis showed that the expression level of DUXAP10 was correlated with tumor size and FIGO stage in clinical patients. Compared with the negative control group, the proliferation ability and cell cloning ability of HO8910 cells overexpressing DUXAP10 were significantly increased (p0.001), while the proliferation and cell cloning ability of A2780 cells interfering with DUXAP10 were significantly decreased (p0.001), indicating that DUXAP10 played a role in promoting the proliferation of ovarian cancer cells.DUXAP10 was significantly overexpressed in ovarian cancer tissues, and its expression was positively correlated with tumor size and FIGO stage in clinical patients. DUXAP10 promoted the proliferation of ovarian cancer cells and was expected to be a predictor and a potential therapeutic target of ovarian cancer.

目的 探索中国骨髓增生异常综合征（MDS）患者基因突变特征。 方法 采用包含112个血液肿瘤相关基因的靶向测序技术对511例MDS患者进行基因突变检测，并回顾性分析其临床资料。 结果 全部511例MDS患者中，共检测到83个突变基因，439例（86%）患者伴有至少1个基因突变。对涉及的83个基因依据其功能进行分类，突变频率依次为表观遗传相关基因（50%）、剪接子相关基因（37%）、信号传导相关基因（34%）、转录因子（24%）和细胞周期与凋亡相关基因（17%）。不同亚型患者的平均基因突变数目分别为：难治性血细胞减少伴单系发育异常（RCUD）1.25个，难治性血细胞减少伴多系发育异常（RCMD）1.73个，难治性贫血伴环状铁粒幼红细胞（RARS）2.79个，难治性贫血伴原始细胞增多-1（RAEB-1）2.22个，RAEB-2 2.34个，MDS伴单纯5q− 2.67个，MDS未分类（MDS-U）2.00个。U2AF1突变患者单纯+8核型异常比例显著增高[Q

This study was aimed for development of vapour-grown carbon nano-fibre(VGCNF)-reinforced aluminium matrix composites by the low-pressure infiltration process. First, VGCNF and Al powder (VGCNF + Alp) preforms for low-pressure infiltration were fabricated by spark sintering process at pressures of 5, 10, 20 and 40 MPa, respectively. Porosity of the preforms fabricated at pressures of 5 and 10 MPa was 44·89 and 40·87%, respectively. However, porosity of the preforms fabricated by spark sintering at pressures of 20 and 40 MPa was approximately 20%. Therefore, VGCNF + Alp/Al composites with the preform sintered at pressures of 5 and 10 MPa were fabricated by the low-pressure infiltration process under an applied pressure of 0·4 MPa, and the relative density was 81·4 and 76·0%, respectively. Moreover, the microstructure, porosity and electrical conductivity of the VGCNF + Alp/Al composites were estimated. Their electrical conductivities reduced with increasing porosity of VGCNF + Alp/Al composites.

The kinetics and mechanism of the CH3 + O reaction and related isomerization-decomposition of CH3O and CH2OH radicals have been studied by ab initio molecular orbital theory based on the CCSD(T)/aug-cc-pVTZ//CCSD/aug-cc-pVTZ, CCSD/aug-cc-pVDZ, and G2M//B3LYP/6-311+G(3df,2p) levels of theory. The predicted potential energy surface of the CH3 + O reaction shows that the CHO + H2 products can be directly generated from CH3O by the TS3 → LM1 → TS7 → LM2 → TS4 path, in which both LM1 and LM2 are very loose and TS7 is roaming-like. The result for the CH2O + H reaction shows that there are three low-energy barrier processes including CH2O + H → CHO + H2 via H-abstraction and CH2O + H → CH2OH and CH2O + H → CH3O by addition reactions. The predicted enthalpies of formation of the CH2OH and CH3O radicals at 0 K are in good agreement with available experimental data. Furthermore, the rate constants for the forward and some key reverse reactions have been predicted at 200-3000 K under various pressures. Based on the new reaction pathway for CH3 + O, the rate constants for the CH2O + H and CHO + H2 reactions were predicted with the microcanonical variational transition-state/Rice-Ramsperger-Kassel-Marcus (VTST/RRKM) theory. The predicted total and individual product branching ratios (i.e., CO versus CH2O) are in good agreement with experimental data. The rate constant for the hydrogen abstraction reaction of CH2O + H has been calculated by the canonical variational transition-state theory with quantum tunneling and small-curvature corrections to be k(CH2O + H → CHO + H2) = 2.28 × 10(-19) T(2.65) exp(-766.5/T) cm(3) molecule(-1) s(-1) for the 200-3000 K temperature range. The rate constants for the addition giving CH3O and CH2OH and the decomposition of the two radicals have been calculated by the microcanonical RRKM theory with the time-dependent master equation solution of the multiple quantum well system in the 200-3000 K temperature range at 1 Torr to 100 atm. The predicted rate constants are in good agreement with most of the available data.

目的 比较地西他滨（DAC）单药与以小剂量阿糖胞苷（Ara-C）为基础的CAG/HAG（阿克拉霉素/高三尖杉酯碱+Ara-C+G-CSF）方案治疗骨髓增生异常综合征（MDS）难治性贫血伴有原始细胞增多（RAEB）的疗效及安全性。 方法 回顾性分析2008年12月至2016年10月中国医学科学院血液病医院MDS诊疗中心121例MDS-RAEB患者临床资料，其中59例接受DAC 20 mg·m−2·d−1×5 d方案治疗，62例接受CAG/HAG方案治疗，比较两组患者的总反应率（ORR）、总生存（OS）率及不良反应发生率。 结果 DAC组、CAG/HAG组患者的ORR分别为66.2%和56.4%，差异无统计学意义（χ2=1.185，P=0.276）。CAG/HAG组1个疗程起效率明显高于DAC组（94.3%对69.2%），两组患者起效疗程数总体比较差异有统计学意义（χ2=7.612，P=0.009）。DAC组中位OS时间为19.5（95%CI 10.5~28.4）个月，CAG/HAG组中位OS时间为20.3（95%CI 10.7~29.9）个月，两组差异无统计学意义（χ2=0.004，P=0.947）。两组患者的不良反应主要是3~4级血细胞减少和相关感染，CAG/HAG组血细胞减少发生率明显高于DAC组（100.0%对64.4%，P

Bragg acoustical hyperstructure can scatter elastic wave, local resonance system can fight against vibration by the reaction force with reversed phase in low-frequency range, for improving the scattering performance of Bragg hyperstructure, a novel composite beam of Bragg beam with local resonator is investigated theoretically. Its dispersion relations and bang gaps are calculated by the established theoretical model. In order to confirm the veritable existence of band gaps, the transmission spectrum of flexural vibration waves are also studied by finite-element method, and comparing the relationship of vibration transmission spectrum and band gaps, the results indicate that the proposed theoretical model can accurately predict the band gaps of the proposed composite beam. For probing the dispersion mechanics, comparing the band gaps and modes shapes of the proposed composite beam with an unalloyed Bragg beam, the results denoted that local resonator can add two band gaps at the base of Bragg beam. Further, the changes of the band gaps that depend on the local resonator and on Bragg beam are studied. It is indicated that the total band gaps can be narrowed when the resonance frequency of the local resonators located at the band gaps of the Bragg beam and the branches will become approximately flat. The band gaps will broaden if the branch that depends on the local resonator gets closer to the branch on Bragg beam.

The kinetics of the C 6 H 5 reactions with CH 3 OH and C 2 H 5 OH has been measured by pulsed-laser photolysis/mass-spectrometry (PLP/MS) employing acetophenone as the radical source. Kinetic modeling of the benzene formed in the reactions over the temperature range 306–771 K allows us to reliably determine the total rate constants for H-abstraction reactions. In order to improve our low temperature measurements down to 304 K we have also applied the cavity ring-down spectrometric technique using nitrosobenzene as the radical source. Both sets of data agree closely. A weighted least-squares analysis of the two complementary sets of data for the two reactions gave the total rate constants k (CH 3 OH) = (7.82 ± 0.44) × 10 11 exp [−(853 ± 30)/ T ] and k (C 2 H 5 OH) = (5.73 ± 0.58) × 10 11 exp [−(1103 ± 44)/ T ] cm 3 mol −1 s −1 for the temperature range studied. Theoretically, four possible product channels of the C 6 H 5 + CH 3 OH reaction producing C 6 H 6 + CH 3 O, C 6 H 6 + CH 2 OH, C 6 H 5 OH + CH 3 and C 6 H 5 OCH 3 + H and five possible product channels of the C 6 H 5 + C 2 H 5 OH reaction producing C 6 H 6 + C 2 H 5 O, C 6 H 6 + CH 2 CH 2 OH, C 6 H 6 + CH 3 CHOH, C 6 H 5 OH + CH 3 CH 2 and C 6 H 5 OCH 2 CH 3 + H have been computed at the G2M//B3LYP/6−311+G(d, p) level of theory. The hydrogen abstraction channels were predicted to have lower energy barriers than those for the substitution reactions and their rate constants were calculated by the microcanonical variational transition state theory at 200–3000 K. The predicted rate constants are in good agreement with the experimental values. Significantly, the rate constant for the CH 3 OH reaction with C 6 H 5 was found to be greater than that for the C 2 H 5 OH reaction and both reactions were found computationally to be dominated by H-abstraction from the hydroxyl group attributable to the affinity of the phenyl toward the OH group and the predicted lower energy barriers for the OH attack.

目的 分析高嗜酸粒细胞综合征(HES)的临床特征和长期疗效。 方法 回顾性分析接受糖皮质激素单药治疗的60例初诊HES患者的临床资料，通过随访获得患者生存情况及死亡原因。 结果 全部60例HES患者中，男45例，女15例，中位年龄38(11~80)岁。常见受累器官依次为皮肤(55.0%)、胃肠道(40.0%)、肺(35.0%)、心脏(13.3%)、血管(10.0%)和神经肌肉(10.0%)。单器官受累27例(45.0%)，2个器官受累22例(36.7%)，2个以上器官受累11例(18.3%)。糖皮质激素中位诱导治疗剂量相当于泼尼松30(15~60)mg/d，治疗总有效率[完全缓解(CR)+部分缓解(PR)]为88.3%(53/60)。联合或更换其他药物后总有效率提升至93.3%(56/60)。38例治疗有效患者至随访截止时仍接受糖皮质激素单药(33例)或联合(5例)维持治疗，糖皮质激素的中位治疗时间为51(5~92)个月，中位维持剂量相当于泼尼松5(1.25~40)mg/d。20例患者因疾病缓解后依从性差或治疗无效停用糖皮质激素。HES患者5年总体生存率为(90.0±4.3)%，主要死亡原因为心脏功能异常。 结论 HES对糖皮质激素治疗敏感，多数疗效欠佳的患者可以通过联合用药改善疗效。心脏功能异常是患者的主要死亡原因。

To evaluate the prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis (PMF).Four hundred and two Chinese patients with PMF were retrospectively analyzed. The Kaplan-Meier method, the Log-rank test, the likelihood ratio test and the Cox proportional hazards regression model were used to evaluate the prognostic scoring system.This cohort of patients included 209 males and 193 females with a median age of 55 years (range: 15- 89). JAK2V617F mutations were detected in 189 subjects (47.0% ), MPLW515 mutations in 13 (3.2%) and CALR mutations in 81 (20.1%) [There were 30 (37.0%) type-1, 48 (59.3%) type-2 and 3 (3.7%) less common CALR mutations], respectively. 119 subjects (29.6%) had no detectable mutation in JAK2, MPL or CALR. Univariate analysis indicated that patients with CALR type-2 mutations or no detectable mutations had inferior survival compared to those with JAK2, MPL or CALR type- 1 or other less common CALR mutations (the median survival was 74vs 168 months, respectively [HR 2.990 (95% CI 1.935-4.619),P0.001]. Therefore, patients were categorized into the high-risk with CALR type- 2 mutations or no detectable driver mutations and the low- risk without aforementioned mutations status. The DIPSS-Chinese molecular prognostic model was proposed by adopting mutation categories and DIPSS-Chinese risk group. The median survival of patients classified in low risk (132 subjects, 32.8% ), intermediate- 1 risk (143 subjects, 35.6%), intermediate- 2 risk (106 subjects, 26.4%) and high risk (21 subjects, 5.2%) were not reached, 156 (95% CI 117- 194), 60 (95% CI 28- 91) and 22 (95% CI 10- 33) months, respectively, and there was a statistically significant difference in overall survival among the four risk groups (P0.001). There was significantly higher predictive power for survival according to the DIPSS-Chinese molecular prognostic model compared with the DIPSS-Chinese model (P=0.005, -2 log-likelihood ratios of 855.6 and 869.7, respectively).The impact of the CALR type- 2 mutations or no detectable driver mutation on survival was independent of current prognostic scoring systems. The DIPSS- Chinese molecular prognostic model based on the molecular features of Chinese patients was proposed and worked well for prognostic indication.

To explore whether the ABL(Δexon7) and ABL(35INS) spliceosome contributed to TKIs resistance.Screening ABL(Δexon7) and ABL(35INS) in 74 normal people and 76 CML patients (53 patients in remission and 23 patients with TKIs resistance) by using polyacrylamide gel electrophoresis combined with cloning sequencing.A novel spliceosome ABL(Δexon7+ 35INS) (ABL(Δexon7) and ABL(3)5INS existed at the same time) was identified and the mutation was detected in 8 (10.8%) of 74 normal people, 4 (7.5%) of 53 remission patients and 2 (8.7%) of 23 resistant patients. While 47 (63.5%) cases expressed ABL(Δexon7) and 8 (10.8% ) cases expressed ABL(35INS) in 74 healthy people, 30 (56.6%) cases expressed ABL(Δexon7) and 5 (9.4% ) cases expressed ABL(35INS) in 53 remission patients, 12 (52.2%) cases expressed ABL(Δexon7) and 3(13.0%) cases expressed ABL(35INS) in 23 resistant patients. Three kinds of spliceosome in all groups had no statistical difference.ABL(Δexon7+ 35INS), ABL(Δexon7) and ABL(35INS) may be not uncommon in ABL gene and were unrelated to resistance in CML with TKIs treatment. ABL(35INS) were often accompanying with exon 7 deletion.

As vapor grown carbon fiber (VGCF) possesses the good mechanical properties, high thermal conductivity, high electrical conductivity and low thermal expansion, VGCF/ Al composites are expected to be suitable materials for a high performance radiator. In this study, VGCF were dipped and treated with ultrasonic vibration in some kinds of solution at first. Then, the mixed powders including three kind of average particle size of Al (1, 3 and 30µm) was milled by wet process with three kinds of solution, which are acetone, ethanol and butanol. Ethanol is most suitable for mixing solution because of homogeneous distribution of VGCF and Al powders. The mixed powders were spark-sintered in order to obtain dense VGCF/Al composites. The densification mechanism of VGCF/Al composites was divided into the plastic deformation (2nd stage) and creep deformation (3rd stage) after the 1st stage of rectangular wave pulse discharge. The densification rate of VGCF/Al composite powder depended on Al powder for matrix, but independent on VGCF. VGCF are dispersed uniformly in the VGCF/1 µm Al composite. But the aggregations of VGCF exhibited a preferential orientation in VGCF/30 µm Al composite, which results from the deformation of Al powders under the uniaxial pressure during the hot pressing in sintering process.

Applying the melt-fluxing method, rapid solidifications of undercooled Cu 50 Co 50 immiscible and Cu 70 Ni 30 solid solution alloys were performed to investigate the grain refinement regularity at moderate undercooling. Due to the essential distinction of physical properties between these alloys, grain refinement phenomenon was detected in Cu 50 Co 50 alloy with a tendency of liquid separation, while dendrite structure appears for Cu 70 Ni 30 alloy. The association of microstructure morphology to non-equilibrium solidification process was constructed with the description of recalescence degree as a function of undercooling. Quantitative thermodynamic calculation for the undercooled liquid of the researched systems was carried out to elucidate the influence of liquid separation on the variation of Gibbs free energy for the subsequent rapid solidification, which gives a better understanding of the as-observed experimental results.